Results 11 to 20 of about 156,396 (269)

Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line [PDF]

Genetics and Molecular Biology, 2023
Genetically antimicrobial resistance in Mycobacterium tuberculosis is currently one of the most important aspects of tuberculosis, considering that there are emerging resistant strains for almost every known drug used for its treatment.
Nicolas de Oliveira Rossini, Marcio Vinicius Bertacine Dias   +1 more
doaj   +1 more source

Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda

The Lancet Microbe, 2020
Summary: Background: The Xpert MTB/RIF (Xpert) assay is used globally to rapidly diagnose tuberculosis and resistance to rifampicin. We investigated the frequency and predictors of false-positive findings of rifampicin resistance with Xpert. Methods: We
Jean Claude Semuto Ngabonziza, MSc, Tom Decroo, PhD, Patrick Migambi, MSc, Yves Mucyo Habimana, MD, Armand Van Deun, PhD, Conor J Meehan, PhD, Gabriela Torrea, PhD, Faridath Massou, PharmD, Willem Bram de Rijk, BS, Bertin Ushizimpumu, BS, Esdras Belamo Niyigena, BS, Emil Ivan, PhD, Jules Mugabo Semahore, MD, Jean Baptiste Mazarati, PhD, Corinne Simone Merle, PhD, Philip Supply, PhD, Dissou Affolabi, ProfPhD, Leen Rigouts, PhD, Bouke Catherine de Jong, ProfPhD   +18 more
doaj   +1 more source

Biodegradable and Bioactive Carriers Based on Poly(betulin disuccinate-co-sebacic Acid) for Rifampicin Delivery

Pharmaceutics, 2022
This paper describes the preparation and characterization of polymer-drug systems based on polymeric microspheres obtained from poly(betulin disuccinate-co-sebacic acid).
Daria Niewolik, Barbara Bednarczyk-Cwynar, Piotr Ruszkowski, Alicja Kazek-Kęsik, Grzegorz Dzido, Katarzyna Jaszcz   +5 more
doaj   +1 more source

The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus

Antibiotics, 2022
Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined the CorA FoM in S.
Jan Balansky, Kenneth Pfarr, Christiane Szekat, Stefan Kehraus, Tilman Aden, Miriam Grosse, Rolf Jansen, Thomas Hesterkamp, Andrea Schiefer, Gabriele M. König, Marc Stadler, Achim Hoerauf, Gabriele Bierbaum   +12 more
doaj   +1 more source

Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India [PDF]

, 2015
Background Xpert MTB/RIF, the first automated molecular test for tuberculosis, is transforming the diagnostic landscape in high-burden settings. This study assessed the impact of up-front Xpert MTB/RIF testing on detection of pulmonary tuberculosis (PTB)
Alavadi, U, Arinaminpathy, N, Babre, A, Boehme, C, Denkinger, C, Dewan, PK, Ghedia, M, Gray, C, Gupta, RS, Kulsange, S, Paramasivan, CN, Parmar, M, Raizada, N, Ramachandran, R, Sachdeva, KS, Sreenivas, A, Thakur, R, Vadera, B, Van den Hof, S, Van't Hoog, AH   +19 more
core   +1 more source

Cell membrane components of Brucella melitensis play important roles in the resistance of low-level rifampicin.

PLoS Neglected Tropical Diseases, 2020
Brucella spp. are facultative intracellular pathogens that can persistently colonize host cells and cause the zoonosis- brucellosis. The WHO recommended a treatment for brucellosis that involves a combination of doxycycline, rifampicin, or streptomycin ...
Xiaowen Yang, Tonglei Wu, Wenxiao Liu, Guozhong Tian, Hongyan Zhao, Dongri Piao, Hai Jiang, Qingmin Wu   +7 more
doaj   +1 more source

Synthesis, in vitro and in vivo evaluation of 3β-[18F]fluorocholic acid for the detection of drug-induced cholestasis in mice [PDF]

, 2017
Introduction : Drug-induced cholestasis is a liver disorder that might be caused by interference of drugs with the hepatobiliary bile acid transporters. It is important to identify this interference early on in drug development.
De Lombaerde, Stef, De Vos, Filip, Devisscher, Lindsey, Kersemans, Ken, Neyt, Sara, Van Vlierberghe, Hans, Vanhove, Christian, Verhoeven, Jeroen   +7 more
core   +3 more sources

High dose rifampicin kills persisters, shortens treatment duration and reduces relapse rate in vitro and in vivo

Frontiers in Microbiology, 2015
Although high-dose rifampicin holds promise for improving tuberculosis control by potentially shortening treatment duration, these effects attributed to eradication of persistent bacteria are unclear. The presence of persistent M.
Yanmin eHu, Alexander eLiu, Fatima eOrtega-Muro, Laura eAlameda-Martin, Denis eMitchison, Anthony eCoates   +5 more
doaj   +1 more source

Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis

Acta Dermato-Venereologica, 2022
Cholestatic itch is a disabling symptom that may be secondary to liver or biliary diseases. Management of cholestatic pruritus is complex. A systematic review and meta-analysis on the efficacy of treatments for cholestatic pruritus were performed. PubMed
Charles Dervout, Nicholas Boulais, Thomas Barnetche, Jean-Baptiste Nousbaum, Emilie Brenaut, Laurent Misery   +5 more
doaj   +1 more source

Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial [PDF]

, 2013
BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Agnès Sobry, Alexandra Calmy, Anne-Marie Taburet, Avihingsanon, Blackwelder, Boulle, Carlota Silva, Chen, Christine Rouzioux, Christophe Michon, Cohen, Cohen, Davies, Dejesus, Dieterich, Elisabeth Baudin, Elizabete Nunes, Flandre, Ford, Gengiah, Gulick, Ilesh Jani, Kwara, Laura Ciaffi, Maartens, Manosuthi, Manosuthi, Maryline Bonnet, Matteelli, Mbuagbaw, Meintjes, Nilesh Bhatt, Rui Bastos, Scourfield, Shipton, Soriano, Swaminathan, Tang, Telenti, van Leth   +39 more
core   +3 more sources